2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Chronic liver disease and hepatic calcium-oxalate deposition in patients with primary hyperoxaluria type I

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Patients with primary hyperoxaluria type I (PH I) are prone to develop early kidney failure. Systemic deposition of calcium-oxalate (CaOx) crystals starts, when renal function declines and plasma oxalate increases. All tissue, but especially bone, heart and eyes are affected. However, liver involvement, as CaOx deposition or chronic hepatitis/fibrosis has never been reported. We examined liver specimen from 19 PH I patients (aged 1.5 to 52 years at sample collection), obtained by diagnostic biopsy (1), at autopsy (1), or transplantation (17). With polarization microscopy, birefringent CaOx crystals located in small arteries, but not within hepatocytes were found in 3/19 patients. Cirrhosis was seen in one, fibrosis in 10/19 patients, with porto-portal and nodular fibrosis (n = 1), with limitation to the portal field in 8 and/or to central areas in 5 patients. Unspecific hepatitis features were observed in 7 patients. Fiber proliferations were detectable in 10 cases and in one sample transformed Ito-cells (myofibroblasts) were found. Iron deposition, but also megakaryocytes as sign of extramedullary erythropoiesis were found in 9, or 3 patients, respectively. Overall, liver involvement in patients with PH I was more pronounced, as previously described. However, CaOx deposition was negligible in liver, although the oxalate concentration there must be highest.

          Related collections

          Most cited references33

          • Record: found
          • Abstract: found
          • Article: found

          Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1

          Primary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by hepatic overproduction of oxalate that leads to kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. Lumasiran, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Primary hyperoxaluria.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              An update on primary hyperoxaluria.

              The autosomal recessive inherited primary hyperoxalurias types I, II and III are caused by defects in glyoxylate metabolism that lead to the endogenous overproduction of oxalate. Type III primary hyperoxaluria was first described in 2010 and further types are likely to exist. In all forms, urinary excretion of oxalate is strongly elevated (>1 mmol/1.73 m(2) body surface area per day; normal 30% of patients with primary hyperoxaluria type I. The fact that such a large proportion of patients have such poor outcomes is particularly unfortunate as ESRD can be delayed or even prevented by early intervention. Treatment options for primary hyperoxaluria include alkaline citrate, orthophosphate, or magnesium. In addition, pyridoxine treatment can be used to normalize or reduce oxalate excretion in about 30% of patients with primary hyperoxaluria type I. Time on dialysis should be short to avoid overt systemic oxalosis. Transplantation methods depend on the type of primary hyperoxaluria and on the particular patient, but combined liver and kidney transplantation is the method of choice in patients with primary hyperoxaluria type I and isolated kidney transplantation is the preferred method in those with primary hyperoxaluria type II. To the best of our knowledge, progression to ESRD has not yet been reported in any patient with primary hyperoxaluria type III.
                Bookmark

                Author and article information

                Contributors
                Bernd.Hoppe@knz-bonn.de
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                6 October 2022
                6 October 2022
                2022
                : 12
                : 16725
                Affiliations
                [1 ]GRID grid.411097.a, ISNI 0000 0000 8852 305X, Department of Pediatric and Adolescent Medicine, Division of Pediatric Nephrology, , University Hospital Cologne, ; Cologne, Germany
                [2 ]GRID grid.490185.1, Department of Pediatric and Adolescent Medicine, , HELIOS University Hospital Wuppertal, ; Wuppertal, Germany
                [3 ]GRID grid.411097.a, ISNI 0000 0000 8852 305X, Institute of Human Genetics, , University Hospital Cologne, ; Cologne, Germany
                [4 ]GRID grid.411484.c, ISNI 0000 0001 1033 7158, Department of Pediatric Nephrology, , Lublin Medical University, ; Lublin, Poland
                [5 ]GRID grid.411097.a, ISNI 0000 0000 8852 305X, Department of Pathology, , University Hospital Cologne, ; Cologne, Germany
                [6 ]Department of Pediatric and Adolescent Medicine, Asklepios Klinik Hamburg, Hamburg, Germany
                [7 ]Department of Pathology, Nuestra Señora de Candelaria University Hospital, Tenerife, Spain
                [8 ]GRID grid.10041.34, ISNI 0000000121060879, Department of Basic Medical Sciences, Centre for Biomedical Research in Rare Diseases (CIBERER), Institute of Biomedical Technologies (ITB), , University of La Laguna, ; Tenerife, Spain
                [9 ]German Hyperoxaluria Center, c/o Kindernierenzentrum Bonn, Bonn, Germany
                Author information
                https://orcid.org/0000-0002-0337-9613
                https://orcid.org/0000-0003-0495-7670
                https://orcid.org/0000-0002-5698-6863
                https://orcid.org/0000-0002-0171-7025
                https://orcid.org/0000-0002-9205-7906
                https://orcid.org/0000-0001-6685-7267
                https://orcid.org/0000-0003-1139-4642
                https://orcid.org/0000-0002-8120-3306
                Article
                19584
                10.1038/s41598-022-19584-9
                9537520
                6ed68d59-9f82-4e6b-802c-18524f7de3cd
                © The Author(s) 2022

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 25 March 2022
                : 31 August 2022
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100010661, Horizon 2020 Framework Programme;
                Award ID: 643578
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100004837, Ministerio de Ciencia e Innovación;
                Award ID: FJC2018-036199-I
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100001659, Deutsche Forschungsgemeinschaft;
                Award ID: SFB/TRR 57
                Award Recipient :
                Funded by: Universitätsklinikum Köln (8977)
                Categories
                Article
                Custom metadata
                © The Author(s) 2022

                Uncategorized
                nephrology,kidney diseases,renal calculi,liver fibrosis
                Uncategorized
                nephrology, kidney diseases, renal calculi, liver fibrosis

                Comments

                Comment on this article